Integral Diagnostics Lifts FY26 Earnings as Capitol Synergies Beat Expectations

Integral Diagnostics posts strong FY26 profit and cash flow growth, beating synergy targets.

What the company is saying

Integral Diagnostics presents FY26 as a year of substantial operational and financial progress, highlighting a 25.6% revenue increase to $788.7 million and a 50.1% rise in operating NPAT to $47.4 million. The core narrative credits higher patient volumes, Medicare indexation, improved modality mix, and the successful Capitol Health integration for these gains. Management emphasizes the achievement of more than $14.0 million in annual ongoing merger synergies, exceeding the $10.0 million target set at the time of the merger. The announcement frames the integration as largely complete, with procurement and teleradiology efficiencies highlighted but not quantified in detail. The tone is confident, underpinned by a 30.3% increase in operating EBITDA to $164.8 million, an 80 basis point margin expansion, and a 50% lift in the fully franked final dividend to 6.0 cents per share. Forward-looking statements focus on sustaining revenue growth, maintaining an EBITDA margin above 21.0%, and further de-gearing into FY27, while also referencing industry tailwinds such as MRI deregulation and the National Lung Cancer Screening Program.

What the data suggests

The disclosed numbers confirm robust financial momentum for FY26: revenue reached $788.7 million, up 25.6%, and operating NPAT rose 50.1% to $47.4 million. Operating EBITDA grew 30.3% to $164.8 million, with the margin expanding to 20.9%. Statutory NPAT jumped to $22.0 million from $2.8 million, and operating free cash flow climbed 30.7% to $106.4 million. The company exceeded its merger synergy target, delivering over $14.0 million in ongoing annual savings versus the $10.0 million expected. Leverage improved to 2.3x EBITDA from 2.6x, while net debt remained steady at $298.9 million and undrawn debt facilities stood at $117.0 million. Organic Australian revenue grew 7.4%, with legacy IDX up 8.9% and legacy Capitol up 5.4%; New Zealand organic revenue rose 2.1% on a constant-currency basis. The group performed about 4.0 million exams for 1.7 million patients, with average fees per Australian exam up 6.5%. Some operational claims, such as the full completion of integration and the direct impact of MRI deregulation, are asserted without granular supporting data, but headline financials are transparent and consistent.

Analysis

The announcement's tone is positive but proportionate to the strong, realised financial and operational results disclosed for FY26. Key metrics such as revenue, operating NPAT, EBITDA, statutory NPAT, free cash flow, and dividend growth are all supported by specific, audited numbers. The majority of claims are realised facts, with only a minority of statements being forward-looking (e.g., targets for FY27 margin and de-gearing). Capital expenditure is disclosed and appears manageable relative to cash flow, with no indication that large outlays are being paired with only long-dated or uncertain returns. The narrative is supported by evidence, and there is no material exaggeration or narrative inflation. The forward-looking statements are clearly separated from realised results and are not used to inflate the current period's achievements.

Risk flags

• ●Integration risk remains, as the announcement asserts that Capitol integration is 'largely complete' but does not provide a detailed breakdown of remaining tasks or potential cost overruns. Without full transparency on integration milestones, there is residual uncertainty about whether all synergies are sustainable.
• ●Operational leverage is exposed to ongoing clinical staff shortages and labour cost inflation, which are acknowledged but not quantified in terms of future impact. If wage pressures accelerate or recruitment lags, margin expansion targets may be at risk.
• ●Capital intensity is moderate, with FY26 capital expenditure at $49.8 million and FY27 guidance of $50.0–$60.0 million. While current cash flow covers these outlays, any shortfall in operating performance or unexpected capex increases could pressure free cash flow and leverage.
• ●Disclosure risk is present in the lack of detailed reconciliations for pro forma merged metrics and the specific contribution of growth drivers like MRI deregulation. This limits independent verification of some operational claims and could mask underlying volatility.
• ●Industry and regulatory risks include reliance on Medicare indexation and government programs such as the National Lung Cancer Screening Program. Any policy changes or funding cuts could affect revenue growth and patient volumes.

Bottom line

Integral Diagnostics delivered strong, realised financial gains in FY26, with revenue, profit, and cash flow all up sharply and merger synergies outperforming targets. The narrative is credible at the headline level, supported by clear year-over-year improvements in core metrics and a 50% increase in the final dividend. Some operational and integration claims lack granular disclosure, leaving minor gaps in transparency, but the main financial story is robust. The company’s ability to sustain margin expansion and further de-gear will depend on managing labour costs, maintaining operational discipline, and navigating industry policy settings. Investors should focus on the durability of synergy savings, the trajectory of organic growth in both Australia and New Zealand, and any changes in capital expenditure or regulatory environment. The most important takeaway is that Integral Diagnostics has delivered on its integration and growth promises for FY26, but continued outperformance will require disciplined execution and transparent reporting.

Announcement summary

(ASX: IDX) Integral Diagnostics lifted FY26 revenue 25.6% to $788.7 million and operating NPAT by 50.1% to $47.4m as higher patient volumes, Medicare indexation, and a favourable modality mix combined with benefits from the Capitol Health integration. Operating EBITDA rose 30.3% to $164.8m, with the EBITDA margin expanding 80 basis points to 20.9%, while statutory NPAT climbed to $22.0m from $2.8m. Annual ongoing merger synergies reached more than $14.0m, exceeding the at least $10.0m expected at the time of the merger. The group declared a fully franked final dividend of 6.0 cents per share, up 50%, while targeting sustainable revenue growth, an EBITDA margin above 21.0%, and further de-gearing in FY27. Organic Australian revenue increased 7.4%, including 8.9% growth from the legacy IDX business and 5.4% from legacy Capitol, while New Zealand organic revenue rose 2.1% on a constant-currency basis. MRI deregulation and the National Lung Cancer Screening Program supported growth during FY26, with Integral Diagnostics holding 42 licensed MRI machines in Australia from July 2025 compared with 23 in the previous corresponding period. Operating free cash flow increased 30.7% to $106.4m, with conversion before replacement capital expenditure of 82.0%, while total FY26 capital expenditure was $49.8m including $21.0m directed to growth initiatives.

Disagree with this article?